Flowchart of the study population. by Emma Hertting (21568077)

“…</p><p>Conclusion</p><p>Identified early-onset FGR fetuses benefited from identification with a decreased risk of stillbirth at the price of an increased risk for severe newborn and childhood outcomes. …”

Mean (±SD) syrup consumption (µL/bee) of adult winter worker bees (n = 180/group) over time (in days) after inoculation with either <i>M. plutonius</i> ATCC 3511 or <i>M. plutonius... by Midhun Sebastian Jose (19336846)

Mean (±SD) sugar consumption (µL/bee) of newly emerged summer worker bees in laboratory inoculated with 1 × 10⁷ CFU/bee <i>M. plutonius</i> 2019BC1 and or treated with o... by Midhun Sebastian Jose (19336846)

Influence of anti-<i>Leishmania</i> compounds added to the sugar diet on the infection of <i>Lu. longipalpis</i> with <i>Le. amazonensis.</i> by Tainá Neves Ferreira (21601579)

Median ± IQR <i>M. plutonius</i> bacterial load (CFU/bee) of adult winter worker bees in the laboratory inoculated with A. <i>M. plutonius</i> ATCC3511 or B. <i>M. plutonius</i> 20... by Midhun Sebastian Jose (19336846)

Mean (±SD) sugar consumption (µL/bee) of adult summer worker bees (n = 180/group) over time (in days) after inoculation with A. one of 6 incremental doses of of <i>M. plutonius</i>... by Midhun Sebastian Jose (19336846)

Median ± IQR <i>M. plutonius</i> bacterial load (CFU/bee) of adult summer worker bees over time after introduction on D3 into field colonies. by Midhun Sebastian Jose (19336846)

Median ± IQR <i>M. plutonius</i> bacterial load (CFU/bee) of caged adult summer worker bees over time after inoculation with A. low (1 × 10⁴ CFU/bee)B. Medium (1 × 10<su... by Midhun Sebastian Jose (19336846)

Median ± IQR <i>M. plutonius</i> bacterial load (CFU/bee) of caged adult summer worker bees (n = 114 bees/group) introduced on day 3 into field colonies later treated 3 times at 4... by Midhun Sebastian Jose (19336846)

The flow-diagram for the randomised clinical study. by Iva Milinkovic (22331710)

Subjects:

Total bacterial count values at baseline and six months after treatment using systemic and local antibiotic treatment. by Iva Milinkovic (22331710)

Subjects:

Mean Values and Standard Deviations (Mean [±SD]) of Clinical Parameters: periodontal probing depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), and plaque ind... by Iva Milinkovic (22331710)

Subjects:

Difference in (a) IL-17, and (b) TNF-α relative gene expression levels between baseline and six months after treatment using systemic and local antibiotic treatment. by Iva Milinkovic (22331710)

Subjects:

Table 1_Gender difference in the association between composite dietary antioxidant index and all-cause mortality.docx by Lanzhi Duan (15350413)

“…The restricted cubic spline revealed that the hazard ratio (HR) of all-cause mortality decreased significantly with increasing CDAI. …”

Quantification of bacterial adhesion revealed a significant decrease in the adhesion of <i>S. aureus</i>, <i>S. epidermidis</i>, and <i>P. aeruginosa</i> on blotted corneas of mice treated with 0.5% bupivacaine (BUP) combined with topical (TOP) application, following subconjunctival injection (SCI) of CGRP, 24 hours before the final BUP treatment (day 14) and again one hour prior to the final bupivacaine injection on day 15. by Ananya Datta (19932144)

Table 2_To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure.docx by Jinyu He (19774641)

“…Compared to conventional therapy or placebo, treatment with MRAs significantly reduced the risk of all-cause mortality (RR = 0.862, 95% CI: 0.778–0.956, p = 0.005; I² = 36.1%), cardiovascular mortality (RR = 0.828, 95% CI: 0.732–0.937, p = 0.003; I² = 45.7%), and heart failure-related hospitalization (RR = 0.780, 95% CI: 0.657–0.926, p = 0.005; I² = 65.5%). …”

Table 1_To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure.docx by Jinyu He (19774641)

“…Compared to conventional therapy or placebo, treatment with MRAs significantly reduced the risk of all-cause mortality (RR = 0.862, 95% CI: 0.778–0.956, p = 0.005; I² = 36.1%), cardiovascular mortality (RR = 0.828, 95% CI: 0.732–0.937, p = 0.003; I² = 45.7%), and heart failure-related hospitalization (RR = 0.780, 95% CI: 0.657–0.926, p = 0.005; I² = 65.5%). …”

Table 3_To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure.docx by Jinyu He (19774641)

“…Compared to conventional therapy or placebo, treatment with MRAs significantly reduced the risk of all-cause mortality (RR = 0.862, 95% CI: 0.778–0.956, p = 0.005; I² = 36.1%), cardiovascular mortality (RR = 0.828, 95% CI: 0.732–0.937, p = 0.003; I² = 45.7%), and heart failure-related hospitalization (RR = 0.780, 95% CI: 0.657–0.926, p = 0.005; I² = 65.5%). …”

Effect of ex vivo treatment with rhTGFβ1 or a TGFβ1 inhibitor on monocyte responses to rgE stimulation. Monocytes and NK cells purified from PBMC collected from 10 RZV recipients (demographics in S4 Table) before vaccination (D0) and 90 days post-vaccination (D90) were combined ex vivo and stimulated with VZV-rgE. A subset of D0 monocyte & NK cocultures was also treated with the TGFβ1 inhibitor LY (D0 LY), and a subset of D90 cocultures were supplemented with rhTGFβ1. The graph shows individual data points, means and p values calculated by Friedman test for repeated measures with FDR correction. LY treatment of cells collected on D0 significantly increased their activation to levels similar to D90. Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0. by Michael J. Johnson (5818168)

“…Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0.…”

Comparison of body weight and food intake of rats in each group. by Shudan Liu (7049483)

Subjects: